Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Andersen

Showing results (521-530 of 530) with videos related to

Pageof 53
Sort By:
You have reached the last page of results.This site can display upto 530 results.
Cell Host & Microbe|June 16, 2017
Antigen Availability Shapes T Cell Differentiation and Function during TuberculosisAlbanus O Moguche, Munyaradzi Musvosvi, Adam Penn-Nicholson, et al.
Science Translational Medicine|October 26, 2018
Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasisNicholas A Scott, Anna Andrusaite, Peter Andersen, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
Nature Communications|March 6, 2014
Mutations in Alström protein impair terminal differentiation of cardiomyocytesLincoln T Shenje, Peter Andersen, Marc K Halushka, et al.
Tuberculosis (Edinburgh, Scotland)|February 3, 2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams, Graham J Hatch, Simon O Clark, et al.
Nature Communications|July 2, 2025
The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trialJohanne K Hansen, Mads Israelsen, Suguru Nishijima, et al.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 14, 2017
Reconsidering the causality of TIA1 mutations in ALSRick A van der Spek, Wouter van Rheenen, Sara L Pulit, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 4, 2013
ALS Untangled No. 20: the Deanna protocol, Christina Fournier, Bedlack Bedlack, et al.
Lancet (London, England)|April 13, 2026
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort studyIsabel Graupera, Maja Thiele, Laurent Castera, et al.
Pageof 53

Showing results (521-530 of 530) with videos related to

Sort By:
Pageof 53
You have reached the last page of results.This site can display upto 530 results.
Cell Host & Microbe|June 16, 2017
Antigen Availability Shapes T Cell Differentiation and Function during TuberculosisAlbanus O Moguche, Munyaradzi Musvosvi, Adam Penn-Nicholson, et al.
Science Translational Medicine|October 26, 2018
Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasisNicholas A Scott, Anna Andrusaite, Peter Andersen, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine P Lindvig, Katrine H Thorhauge, Johanne K Hansen, et al.
Nature Communications|March 6, 2014
Mutations in Alström protein impair terminal differentiation of cardiomyocytesLincoln T Shenje, Peter Andersen, Marc K Halushka, et al.
Tuberculosis (Edinburgh, Scotland)|February 3, 2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosisAnn Williams, Graham J Hatch, Simon O Clark, et al.
Nature Communications|July 2, 2025
The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trialJohanne K Hansen, Mads Israelsen, Suguru Nishijima, et al.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 14, 2017
Reconsidering the causality of TIA1 mutations in ALSRick A van der Spek, Wouter van Rheenen, Sara L Pulit, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 4, 2013
ALS Untangled No. 20: the Deanna protocol, Christina Fournier, Bedlack Bedlack, et al.
Lancet (London, England)|April 13, 2026
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort studyIsabel Graupera, Maja Thiele, Laurent Castera, et al.
Pageof 53